secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001193125-24-279715
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi prices $50M underwritten offering of 12.5M shares at $4.00 per share
--------------------------------------------------------------------------

- Offering of 12.5M shares at $4.00/share; net proceeds ~$46.7M after underwriting discounts and expenses.
- Participants include Adage Capital, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital, Vivo Capital.
- Expected to close on December 17, 2024, subject to customary conditions.
- Company developing Haduvio for chronic cough in IPF and refractory chronic cough.
- Leerink Partners, Stifel, and Oppenheimer are joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312524279715/0001193125-24-279715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312524279715/d738809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-279715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer